• Like
Strategic Management Market,Market Research Reports, Market Research, Industry Analysis,Market Share,Market Size,marketing research
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

Strategic Management Market,Market Research Reports, Market Research, Industry Analysis,Market Share,Market Size,marketing research

  • 2,237 views
Published

Case studies illustrate how companies of various sizes and types (including Pfizer, Wyeth Pharmaceuticals, Bayer Schering Pharma, and Genzyme) have addressed their portfolio management issues. …

Case studies illustrate how companies of various sizes and types (including Pfizer, Wyeth Pharmaceuticals, Bayer Schering Pharma, and Genzyme) have addressed their portfolio management issues. Strategic Management of Resources and Portfolios: Structuring Risk to Maximize Opportunity in Pharmaceutical R&D concludes by distilling our evaluation of this mission-critical function into actionable recommendations for sound project evaluation and portfolio management.

Published in Business , News & Politics
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Be the first to comment
    Be the first to like this
No Downloads

Views

Total Views
2,237
On SlideShare
0
From Embeds
0
Number of Embeds
0

Actions

Shares
Downloads
38
Comments
0
Likes
0

Embeds 0

No embeds

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
    No notes for slide

Transcript

  • 1. Strategic Management of Resources and Portfolios By ReportsnReportsAs a company develops its business, resources will always be limited and risk will always beinvolved. This is especially true for companies operating in the high-risk life scienceindustry. To stay on top of the changing pharmaceutical R&D environment, certainmeasures must be implemented. This report analyzes: Types of risk that must be faced; Ways that various risks can be assessed and managed; How corporate resources can be allocated to meet the goals and create maximum value according to the corporate strategy.Buy Now: Management of Resources and PortfoliosBrowse All: Newly Published Market Research ReportsManagement of risks, resources, and portfolios are key challenges for any life sciencecompany that seeks to survive the difficult times through which the industry is now passing.There is ample evidence that the entire sector is in the process of restructuring, initiallytaking a defensive stance to defend earning streams but actually building momentumtoward renewed initiatives on a broad front. The restructured industry that will come roaringback within the next few years will consist of leaner and more effective companies.Certainly, all of these survivors will have learned how to manage their risks and resourcesstrategically.For a life science company, risk comes in many forms, with compound attrition being themost obvious. Strategic Management of Resources and Portfolios: Structuring Risk toMaximize Opportunity in Pharmaceutical R&D examines the types of risks that must befaced (e.g., candidate failure, regulatory risk, legal risk, risk management for launcheddrugs, commercial and competitor risk, intellectual property risk, operational risk) andshows that these risks can be mitigated and managed if addressed proactively.Intimately associated with the risk issue is the valuation of projects and portfolios. Weoutline the major approaches by which objective and quantitative valuation of drugdevelopment can be attempted.Many resource-intense corporate operations show extensive potential for streamlining. Wepresent process optimization and quality control approaches that can result in remarkablesavings. These include the “Lean” and “Six Sigma” concept, and the proactive managementof laboratory equipment (including service contracts) and inventories.On a strategic level, resource allocation management can largely be equaled with portfoliomanagement. We evaluate models and approaches for optimal portfolio planning andmanagement, demonstrating that implementation of sound, data-driven, transparent
  • 2. decision processes is paramount. Also described are advanced software suites that areavailable to help manage the huge corporate data streams on the operational plane (i.e.,enterprise resource management) and on the level of business intelligence, where internaldata warehouses are analyzed to provide key figures and profiles that aid in decision-making.Case studies illustrate how companies of various sizes and types (including Pfizer, WyethPharmaceuticals, Bayer Schering Pharma, and Genzyme) have addressed their portfoliomanagement issues. Strategic Management of Resources and Portfolios: Structuring Risk toMaximize Opportunity in Pharmaceutical R&D concludes by distilling our evaluation of thismission-critical function into actionable recommendations for sound project evaluation andportfolio management.Table of ContentsChapter 1 ACCEPTING STRUCTURED RISK TO REALIZE OPPORTUNITY: THEESSENCE OF ENTREPRENEURSHIP1.1. Nature and Dictates of the Risk/Resource Relation1.2. Business Complexity: “Home-Grown” Risk or Business Perspective1.3. Projects, Portfolios, and StrategyDevelopment Strategies of Life Science CompaniesPortfolios: High-Level Implementation of StrategyProjects: Tactical Materialization of Strategy Within the PortfolioChapter 2 DRUG R&D AS AN ENVIRONMENT TASKED TO DELIVER EFFICACY2.1. From Return on Resources to Return on Investment2.2. Proactive R&D Inventory Management and Optimization2.3. Outsourcing Equipment Asset Management2.4. User-Based Management of Consumables and “Soft” Assets2.5. Process Engineering and the Six Sigma ConceptSix Sigma in Pharmaceutical Marketing and SalesSix Sigma and Clinical Development2.6. Reporting and Reviewing in R&DChapter 3 UNDERSTANDING AND ASSESSING DRUG DEVELOPMENT RISK/BENEFITBALANCE3.1. Real Options Analysis: Financial Metrics for R&D ValuationValuation in Development ProjectsReal Options Analysis as a Solution to the Valuation DilemmaImplementing Real Options Analysis
  • 3. 3.2. Valuation of Intellectual PropertyPatentsPatent Valuation3.3. Predictive Safety from Discovery to the Phase I Clinical Stage3.4. Phase II Study Designs and Relevance of Data3.5. Phase III Programs and Prediction of “Field Performance”Chapter 4 RISK AND RESOURCE REQUIREMENT THROUGHOUT THE DRUG LIFECYCLE4.1. Scientific and Clinical Development RiskRisk and Resources from Discovery to INDPhase I Risks and the Consequences of the TGN-1412 AffairPhase IIPhase III4.2. Regulatory Risk4.3. Legal RiskLegal Challenges During DevelopmentLawsuits Concerning Approved Drugs4.4. Risk Management for Launched DrugsFormal Postmarketing Surveillance SystemsHandling Unexpected Adverse Events4.5. Commercial and Competitor RiskMarket Risk from New Scientific DataMarket Risk from a Changing Competitive Situation4.6. Intellectual Property RiskEvolving Patent RegulationsPatent Reform Act of 2007
  • 4. Circumvention of Patents and Challenge by Claiming Different UseCircumvention Risk Case Study #1: AmlodipineCircumvention Risk Case Study #2: Viagra and LevitraCircumvention Risk Case Study #3: Gabapentin4.7. Operational Risk: Failure of ExecutionChapter 5 PORTFOLIO MANAGEMENT: ACTING ON PORTFOLIO RISK/RETURN-ON-INVESTMENT BALANCE5.1. Prioritization as the Key Issue5.2. The Human Factor in Portfolio Management5.3. Portfolios and the Planning Process: Building the ModelsBenchmarking in a Dynamic R&D EnvironmentManaging Portfolio Resource BottlenecksClassical Decision AnalysisMonte Carlo Simulation of OutcomesRobustness Against Multiple Outcome ScenariosAdaptive Clinical Trials: An Emerging Challenge to Resource Management5.4. Enhancing the Portfolio Through M&A and Inlicensing5.5. Decision Support Software from Contact Management to Business IntelligenceCRM, PLM, SCM: Operating with Basic ResourcesEnterprise Resource Planning Software: The Great Operative IntegratorPortfolio Management Software for the Life SciencesDecisionIris (Visual i/o)Enrich Portfolio SystemPDWare PortfolioProModel Portfolio Simulator and Pharma R&D SolutionsData Warehouses and Business Intelligence Software for Strategy SupportExplicit Risk Analysis Software ToolsProduct Life Cycle Management5.6. Managing Data Security in the Digital Business
  • 5. Chapter 6 CASE STUDIES IN PORTFOLIO RESOURCE ALLOCATION6.1. Pfizer6.2. Wyeth Pharmaceuticals6.3. Bayer Schering Pharma6.4. Genzyme Corporation6.5. Three Examples from the Strategic Decisions GroupChapter 7SYNOPSIS AND RECOMMENDATIONS7.1. Evaluation of a Project7.2. Portfolio ManagementReferencesCompany Index with Web AddressesLatest Market Research Reports: MVNO Business Plan with Financial Modeling Spreadsheet Silver, Powders and Flakes : 2011 Lifesciences IT – 2011 Yearbook Time and Cost Reduction in Clinical Trials- Outsourcing and IT to Optimize Patient Recruitment, Logistics, Data and Site Management Opioids Market to 2017 – Steady Uptake of Oxycontin and High Incidence Of Diseases Such As Cancer And Arthritis to Drive the Market Power Market in Western Europe to 2020 – Government Policies Downplaying the Nuclear Energy Industry and Spurring the Growth of Renewable EnergyAbout Us:ReportsnReports is an online library of over 75,000 market research reports and in-depthmarket research studies & analysis of over 5000 micro markets. We provide 24/7 online andoffline support to our customers. Get in touch with us for your needs of market researchreports.Contact:Mr.Priyank7557 Rambler road,Suite727,Dallas,TX75231Tel: +1-888-989-8004E-mail: sales@reportsnreports.comhttp://www.reportsnreports.com